In particular, robust biomarkers are in demand for HER2-positive disease to improve selection of patients for current and emerging therapies of HER2-positive metastatic BC (5) as well as for prediction of resistance for anti-HER2 therapies, recurrence (6, 7), and particular consequences of the disease (8). This evidence concerns the gene ERBB2 and breast cancer.